PDCD1 and neoplasm: iOmx Therapeutics has developed next-generation cancer immunotherapies with a focus on IMT-18, an antibody targeting IGSF11 to overcome tumor-induced immune suppression, particularly in PD-1/PD-L1-resistant tumors.